Cargando…
A novel medication decision gene signature predicts response to individualized therapy and prognosis outcomes in hepatocellular carcinoma patients
Molecular targeted therapy has shown potential in hepatocellular carcinoma (HCC) patients, and immunotherapy applications are developing rapidly. However, clinical guidance for making individualized therapy decisions for HCC patients remains lacking. MDH (Medication Decision in HCC) gene signatures...
Autores principales: | Yuan, Jingsheng, Liu, Zijian, Wu, Zhenru, Yan, Lvnan, Yang, Jiayin, Shi, Yujun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585274/ https://www.ncbi.nlm.nih.gov/pubmed/36275751 http://dx.doi.org/10.3389/fimmu.2022.990571 |
Ejemplares similares
-
HDLBP-stabilized lncFAL inhibits ferroptosis vulnerability by diminishing Trim69-dependent FSP1 degradation in hepatocellular carcinoma
por: Yuan, Jingsheng, et al.
Publicado: (2022) -
HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation
por: Yuan, Jingsheng, et al.
Publicado: (2022) -
Comprehensive Molecular Analysis Identified an SRSF Family-Based Score for Prognosis and Therapy Efficiency Prediction in Hepatocellular Carcinoma
por: Yuan, Jingsheng, et al.
Publicado: (2022) -
Construction of Two Independent RAB Family-Based Scoring Systems Based on Machine Learning Algorithms and Definition of RAB13 as a Novel Therapeutic Target for Hepatocellular Carcinoma
por: Jiang, Chenhao, et al.
Publicado: (2023) -
Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis
por: Yan, Zongcai, et al.
Publicado: (2021)